MedTrace Logo

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

NCT03182751 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2023-03-30

Study results available
· View outcomes & findings →

Summary

Intertrochanteric hip fractures typically result in blood loss from the fracture and require surgery that can cause further blood loss. This study is being done to look at a medication called tranexamic acid which may reduce blood loss and the need for blood transfusions associated with surgery.

Conditions

  • Hip Fractures
  • Intertrochanteric Fractures

Interventions

DRUG

Tranexamic Acid (TXA)

Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient

Sponsors & Collaborators

Principal Investigators

  • Brandon Yuan, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2022-05-24
Completion
2022-05-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03182751 on ClinicalTrials.gov